Will GnRH antagonists provide new hope for patients considered `difficult responders' to GnRH agonist protocols?

Emperaire, J.C. and Ruffie, A. (1991) Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. Hum. Reprod., 6, 506–510.

Fleming, R., Adam, A.H., Barlow, D.H. et al. (1982) A new systematic treatment for infertile women with abnormal hormone profiles. Br. J. Obstet. Gynaecol., 89, 80–83.

Kenigsberg, D., Littman, B.A. and Hodgen, G.D. (1984a) Medical hypophysectomy: I. Dose-response using a gonadotrophin releasing hormone antagonist. Fertil. Steril., 42, 112–115.

Kenigsberg, D., Littman, B.A., Williams, R.F. and Hodgen, G.D. (1984b) Medical hypophysectomy: II. Variability of ovarian response to gonadotrophin therapy. Fertil. Steril., 42, 116–126.

Leung, P.C.K. (1999) GnRH receptor and potential action in human ovary. Gynaecol. Endocrinol., 13, 10.

Olivennes, F., Fanchin, R., Bouchard, P. et al. (1994) The single or dual administration of the gonadotrophin-releasing hormone antagonist Cetrorelix is an in vitro fertilization–embryo transfer programme. Fertil. Steril., 62, 468–476.

Olivennes, F., Alvarez, S., Bouchard, R. et al. (1998) The use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF–embryo transfer; a dose finding study of 3 versus 2 mg. Hum. Reprod., 13, 2411–2414.

Porter, R.N., Smith, W., Craft, I.L. et al. (1984) Induction of ovulation for in vitro fertilization using Buserelin and gonadotrophins. Lancet, ii, 1284–1285.